12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million.
Recap: Marinus Pharmaceuticals Q4 Earnings
Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q4 earnings results on Monday, March 21, 2022 at 07:15 AM.
Here's what investors need to know about the announcement.
Marinus Pharmaceuticals Q4 EPS $(0.77) Misses $(0.76) Estimate, Sales $1.52M Miss $3.37M Estimate
Marinus Pharmaceuticals (NASDAQ:MRNS) reported quarterly losses of $(0.77) per share which missed the analyst consensus estimate of $(0.76) by 1.32 percent. This is a 40 percent decrease over losses of $(0.55) per share
Earnings Scheduled For March 21, 2022
Companies Reporting Before The Bell
• Marinus Pharmaceuticals (NASDAQ:MRNS) is likely to report quarterly loss at $0.76 per share on revenue of $3.37 million.
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.
Here’s Why Marinus Pharmaceuticals Shares Are Moving
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shares are trading higher by 25.0% at $10.72 after the company announced the FDA has approved ZTALMY oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder.
Marinus Pharmaceuticals Announces FDA Approval Of Ztalmy (ganaxolone) For CDKLDeficiency Disorder; Shares Halted On Circuit Breaker
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration
Preview: Marinus Pharmaceuticals’s Earnings
Marinus Pharmaceuticals (NASDAQ:MRNS) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement.
Analysts estimate that Marinus Pharmaceuticals will report an earnings per share (EPS) of $-0.76.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows.